BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 22257339)

  • 1. Eudragit(®) RS PO/RL PO as rate-controlling matrix-formers via roller compaction: Influence of formulation and process variables on functional attributes of granules and tablets.
    Dave VS; Fahmy RM; Bensley D; Hoag SW
    Drug Dev Ind Pharm; 2012 Oct; 38(10):1240-53. PubMed ID: 22257339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Near-infrared spectroscopic analysis of the breaking force of extended-release matrix tablets prepared by roller-compaction: influence of plasticizer levels and sintering temperature.
    Dave VS; Fahmy RM; Hoag SW
    Drug Dev Ind Pharm; 2015 Jun; 41(6):898-905. PubMed ID: 24785574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Citric acid as a solid-state plasticizer for Eudragit RS PO.
    Schilling SU; Shah NH; Malick AW; Infeld MH; McGinity JW
    J Pharm Pharmacol; 2007 Nov; 59(11):1493-500. PubMed ID: 17976259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of processing parameters and formulation factors on the drug release from tablets powder-coated with Eudragit L 100-55.
    Sauer D; Zheng W; Coots LB; McGinity JW
    Eur J Pharm Biopharm; 2007 Sep; 67(2):464-75. PubMed ID: 17451929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Solid-state plasticization of an acrylic polymer with chlorpheniramine maleate and triethyl citrate.
    Zhu Y; Shah NH; Malick AW; Infeld MH; McGinity JW
    Int J Pharm; 2002 Jul; 241(2):301-10. PubMed ID: 12100857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel electrostatic dry coating process for enteric coating of tablets with Eudragit® L 100-55.
    Qiao M; Zhang L; Ma Y; Zhu J; Xiao W
    Eur J Pharm Biopharm; 2013 Feb; 83(2):293-300. PubMed ID: 23183445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of plasticizer level on the drug release from sustained release film coated and hot-melt extruded dosage forms.
    Zhu Y; Mehta KA; McGinity JW
    Pharm Dev Technol; 2006; 11(3):285-94. PubMed ID: 16895839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and characterization of ibuprofen pellets based on Eudragit RS PO and RL PO or their combination.
    Abbaspour MR; Sadeghi F; Garekani HA
    Int J Pharm; 2005 Oct; 303(1-2):88-94. PubMed ID: 16153792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between drug dissolution and leaching of plasticizer for pellets coated with an aqueous Eudragit S100:L100 dispersion.
    Bando H; McGinity JW
    Int J Pharm; 2006 Oct; 323(1-2):11-7. PubMed ID: 16815652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and study of ibuprofen disintegrating sustained-release tablets comprising coated pellets.
    Abbaspour MR; Sadeghi F; Afrasiabi Garekani H
    Eur J Pharm Biopharm; 2008 Mar; 68(3):747-59. PubMed ID: 17977701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of matrix-based theophylline sustained-release microtablets.
    Rey H; Wagner KG; Wehrlé P; Schmidt PC
    Drug Dev Ind Pharm; 2000 Jan; 26(1):21-6. PubMed ID: 10677806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Properties of melt extruded enteric matrix pellets.
    Schilling SU; Shah NH; Waseem Malick A; McGinity JW
    Eur J Pharm Biopharm; 2010 Feb; 74(2):352-61. PubMed ID: 19782133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissolution characteristics of megaloporous tablets prepared with two kinds of matrix granules.
    Ozgüney I; Ertan G; Güneri T
    Farmaco; 2004 Jul; 59(7):549-55. PubMed ID: 15231431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of formulation and process variables on in vitro release of theophylline from directly-compressed Eudragit matrix tablets.
    Ceballos A; Cirri M; Maestrelli F; Corti G; Mura P
    Farmaco; 2005; 60(11-12):913-8. PubMed ID: 16129436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tableting of Eudragit RS and propranolol hydrochloride solid dispersion: effect of particle size, compaction force, and plasticizer addition on drug release.
    Sadeghi F; Afrasiabi Garekani H; Goli F
    Drug Dev Ind Pharm; 2004 Aug; 30(7):759-66. PubMed ID: 15491053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled release of a poorly water-soluble drug from hot-melt extrudates containing acrylic polymers.
    Zhu Y; Shah NH; Malick AW; Infeld MH; McGinity JW
    Drug Dev Ind Pharm; 2006 Jun; 32(5):569-83. PubMed ID: 16720412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Permeability and swelling studies on free films containing inulin in combination with different polymethacrylates aimed for colonic drug delivery.
    Akhgari A; Farahmand F; Afrasiabi Garekani H; Sadeghi F; Vandamme TF
    Eur J Pharm Sci; 2006 Jul; 28(4):307-14. PubMed ID: 16713201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Citric acid monohydrate as a release-modifying agent in melt extruded matrix tablets.
    Schilling SU; Bruce CD; Shah NH; Malick AW; McGinity JW
    Int J Pharm; 2008 Sep; 361(1-2):158-68. PubMed ID: 18582547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation and evaluation of sustained-release matrix tablets based on metoprolol and an acrylic carrier using injection moulding.
    Quinten T; Andrews GP; De Beer T; Saerens L; Bouquet W; Jones DS; Hornsby P; Remon JP; Vervaet C
    AAPS PharmSciTech; 2012 Dec; 13(4):1197-211. PubMed ID: 22965662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation development and in vitro evaluation of theophylline microcapsules.
    Ahmad M; Akhtar N; Murtaza G; Hussain SW
    Pak J Pharm Sci; 2012 Jan; 25(1):15-9. PubMed ID: 22186304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.